Search Result

Results for "

reactivator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Apoptosis (5) Autophagy (1) Bacterial (3) BCL6 (2) CD3 (1) CDK (1) Cholinesterase (ChE) (6) DNA Methyltransferase (2) EBV (1) Endogenous Metabolite (1) Epigenetic Reader Domain (2) FAK (1) Ferroptosis (1) Glucocorticoid Receptor (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV (4) MDM-2/p53 (9) Parasite (1) PD-1/PD-L1 (2) Phosphatase (1) Proteasome (2) TNF Receptor (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (1) Endocrinology (1) Infection (5) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (8)

By Targets:

Adenosine Receptor (1)

Apoptosis (5)

Autophagy (1)

Bacterial (3)

BCL6 (2)

CD3 (1)

CDK (1)

Cholinesterase (ChE) (6)

DNA Methyltransferase (2)

EBV (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (2)

FAK (1)

Ferroptosis (1)

Glucocorticoid Receptor (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HIV (4)

MDM-2/p53 (9)

Parasite (1)

PD-1/PD-L1 (2)

Phosphatase (1)

Proteasome (2)

TNF Receptor (1)

By Research Areas:

Cancer (27)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1200

Pralidoxime chloride 2-PAM chloride	Cholinesterase (ChE)	Neurological Disease
Pralidoxime chloride is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime chloride reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime chloride is an antidote for organophosphate poisoning .

HY-A0280

Roslin 2 bromide Benzylhexamethylenetetramine bromide	MDM-2/p53 FAK	Cancer
Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator with anticancer effects. Roslin 2 bromide binds FAK, disrupts the binding of FAK and p53 .

HY-128974

N-Dodecyl-β-D-maltoside 2 Publications Verification Lauryl Maltoside	Others	Others
N-Dodecyl-β-D-maltoside (Lauryl Maltoside) is a non-ionic detergent. N-Dodecyl-β-D-maltoside has strong adsorption on alumina, titanium dioxide and hematite. N-Dodecyl-β-D-maltoside can promote the reactivation of various proteins. N-Dodecyl-β-D-maltoside can effectively stabilize photoactive reaction center complexes (RCs) and inhibit the degradation of Rhodopseudomonas spheroides R-26 reaction center in solution. N-Dodecyl-β-D-maltoside can be used for purification and stabilization of RNA polymerase and for detection of protein-lipid interactions .

HY-144762

K027	Cholinesterase (ChE)	Neurological Disease
K027 is a potent reactivator of Organophosphates (OP)-inhibited acetylcholinesterase (AChE). K027 can be used for the research of Alzheimer's disease .

HY-155284

K1833	Cholinesterase (ChE)	Neurological Disease
K1833 is a hrAChE inhibitor/reactivator, with an IC₅₀ of 58 μM. K1833 also shows high inhibition (IC₅₀=0.57μM) and low reactivation for hrBChE .

HY-B1738

Pralidoxime
Pralidoxime is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime is an antidote for organophosphate poisoning .

HY-B1738A

Pralidoxime iodide	Cholinesterase (ChE)	Neurological Disease
Pralidoxime iodide is a potent reactivator of acetylcholinesterase (AChE). Pralidoxime iodide reactivates nerve agent-inhibited AChE via direct nucleophilic attack by the oxime moiety on the phosphorus center of the bound nerve agent. Pralidoxime iodide is an antidote for organophosphate poisoning .

HY-156399

KR-27425

Endogenous Metabolite Neurological Disease

AChE activator 1 (compound 13) is a non-pyridinium oxime reactivator of paraoxon-inhibited acetylcholinesterase(AChE) .
HY-146959

K203

Cholinesterase (ChE) Neurological Disease

K203 is a potent reactivator of tabun-inhibited AChE. K203 is a crucial antidote used for the organophosphate intoxication .
HY-156967

BAY 1892005

MDM-2/p53 Cancer

BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .

KR-27425	Endogenous Metabolite	Neurological Disease
AChE activator 1 (compound 13) is a non-pyridinium oxime reactivator of paraoxon-inhibited acetylcholinesterase(AChE) .

K203	Cholinesterase (ChE)	Neurological Disease
K203 is a potent reactivator of tabun-inhibited AChE. K203 is a crucial antidote used for the organophosphate intoxication .

BAY 1892005	MDM-2/p53	Cancer
BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .

HY-160209

KIO-301	Others	Cardiovascular Disease
KIO-301 is a photoswitchable HCN channel blocker, and can be used as the vitreous “light switch” molecule that reactivates retinitis pigmentosa .

HY-19980A

PRIMA-1 2 Publications Verification NSC-281668	Autophagy MDM-2/p53 Ferroptosis Apoptosis	Cancer
PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.

HY-120122

PK7088	Others	Cancer
PK7088 is a pyrazole and a specific peptide. PK7088 supports the reactivation of mutant p53 by converting it to a form exhibiting wild-type properties. PK7088 exhibit anticancer activity in cancer research .

HY-W011108

Obidoxime dichloride	Cholinesterase (ChE)	Neurological Disease
Obidoxime dichloride is a non-full spectrum oxime agent and can be used as an antidote for organophosphate nerve agent poisoning. Obidoxime dichloride reactivates sarin-inhibited acetylcholinesterase (AChE) and reduces acute toxicity of sarin-evaluated .

HY-P99572

Tecaginlimab BNT-312; DuoBody-CD40x-4-1BB; GEN1042	TNF Receptor	Inflammation/Immunology Cancer
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .

HY-18634

NSC319726 ZMC1	MDM-2/p53	Cancer
NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.

HY-123794

MP07-66	Phosphatase	Cancer
MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation .

HY-120012

Mizacorat 4 Publications Verification AZD9567	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
Mizacorat (AZD9567; compound 15) is a potent, oral active, non-steroidal and selective glucocorticoid receptor modulator (SGRM), with an IC₅₀ of 3.8 nM. Exhibits excellent efficacy in the streptococcal cell wall (SCW) reactivation model of joint inflammation .

HY-103397

Nanaomycin A	DNA Methyltransferase Parasite	Infection Cancer
Nanaomycin A is the first selective DNMT3B inhibitor with an IC₅₀ of 500 nM. Nanaomycin A, a quinone antibiotics, reactivates silenced tumor suppressor genes in human cancer cells . Nanaomycin A inhibits in vitro growth of the human malaria parasite Plasmodium falciparum with an IC₈₀ value of 33.1 nM .

HY-13642

RG108 5+ Cited Publications N-Phthalyl-L-tryptophan	DNA Methyltransferase	Cancer
RG108 (N-Phthalyl-L-tryptophan) is a non-nucleoside DNA methyltransferases (DNMTs) inhibitor (IC₅₀=115 nM) that blocks the DNMTs active site. RG108 (N-Phthalyl-L-tryptophan) causes demethylation and reactivation of tumor suppressor genes, but it does not affect the methylation of centromeric satellite sequences .

HY-149886

HIF-2α-IN-9	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC₅₀=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-122753

SLMP53-1	MDM-2/p53	Cancer
SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .

HY-119490

UMB-136	Epigenetic Reader Domain HIV	Infection
UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb .

HY-100468

REV7/REV3L-IN-1	Others	Cancer
REV7/REV3L-IN-1 is a REV7/REV3L interaction inhibitor with an IC₅₀ of 78 μM, which directly binds to REV7 in nuclear magnetic resonance analyses, and inhibits the reactivation of a reporter plasmid containing an interstrand crosslink (ICL) in between the promoter and reporter regions .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

HY-161138

WK369	BCL6 Apoptosis	Cancer
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .

HY-143653

BCL6-IN-6	BCL6	Cancer
BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-161344

Z36-MP5	Others	Cancer
Z36-MP5 is an Mi-2β-targeted inhibitor, with IC₅₀ of 0.082 μM. Z36-MP5 can reduce Mi-2β ATPase activity and reactivates ISG transcription. Z36-MP5 can stimulate T-cell-mediated cytotoxicity .

HY-149577

EBV lytic cycle inducer-1	EBV	Cancer
Epstein-Barr virus (EBV) lytic cycle inducer-1 Dp44mT (compound C7) is an iron-chelatoe-like compound. Dp44mT cooperates with HDAC inhibitor Romidespin (HY-15149) and SAHA to induce EBV lytic cycle. Dp44mT reactivates EBV lytic cycle by activating the ERK1/2-autophagy axis in epithelial cancers .

HY-N0401A

(Z)-Ligustilide 2 Publications Verification	Bacterial	Infection Metabolic Disease
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-13207

ONX-0914 Maximum Cited Publications 14 Publications Verification PR-957	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-153202

SLMP53-2	MDM-2/p53 Apoptosis	Cancer
SLMP53-2 is a mutant p53 reactivator. SLMP53-2 restores wild-type-like conformation and DNA-binding ability of mutp53-Y220C by enhancing its interaction with the Hsp70, leading to the reestablishment of p53 transcriptional activity. SLMP53-2 can induce cell cycle arrest, apoptosis and endoplasmic reticulum (ER) stress. SLMP53-2 exhibits antitumor activity .

HY-13207A

ONX-0914 TFA Maximum Cited Publications 14 Publications Verification PR-957 TFA	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-109139

Taminadenant 1 Publications Verification NIR178; PBF509	Adenosine Receptor	Neurological Disease Cancer
Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A_2A receptor (A_2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with K_B values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .

HY-15815

Bromosporine 3 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

HY-19896

COTI-2 2 Publications Verification	MDM-2/p53 Apoptosis	Cancer
COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-122578

P53R3	MDM-2/p53	Cancer
P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 ^R175H, p53 ^R248W and p53 ^R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 ^M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

Bavituximab Anti-Human Phosphatidylserine Recombinant Antibody	Inhibitory Antibodies	Cancer
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks